Compare Abbott India with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs IPCA LABS - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA IPCA LABS ABBOTT INDIA/
IPCA LABS
 
P/E (TTM) x 47.0 22.9 204.7% View Chart
P/BV x 13.5 4.4 302.4% View Chart
Dividend Yield % 0.5 0.1 486.5%  

Financials

 ABBOTT INDIA   IPCA LABS
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
IPCA LABS
Mar-18
ABBOTT INDIA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs6,110695 878.6%   
Low Rs3,996400 999.0%   
Sales per share (Unadj.) Rs1,552.2260.2 596.6%  
Earnings per share (Unadj.) Rs188.819.0 995.2%  
Cash flow per share (Unadj.) Rs196.433.1 594.2%  
Dividends per share (Unadj.) Rs55.001.00 5,500.0%  
Dividend yield (eoy) %1.10.2 596.2%  
Book value per share (Unadj.) Rs796.6213.0 373.9%  
Shares outstanding (eoy) m21.25126.20 16.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.32.1 154.6%   
Avg P/E ratio x26.828.9 92.7%  
P/CF ratio (eoy) x25.716.6 155.3%  
Price / Book Value ratio x6.32.6 246.7%  
Dividend payout %29.15.3 552.7%   
Avg Mkt Cap Rs m107,37669,120 155.3%   
No. of employees `0003.313.3 25.1%   
Total wages/salary Rs m3,9377,359 53.5%   
Avg. sales/employee Rs Th9,929.32,477.4 400.8%   
Avg. wages/employee Rs Th1,185.1555.2 213.4%   
Avg. net profit/employee Rs Th1,207.7180.6 668.6%   
INCOME DATA
Net Sales Rs m32,98532,836 100.5%  
Other income Rs m1,170418 279.9%   
Total revenues Rs m34,15533,254 102.7%   
Gross profit Rs m5,2454,505 116.4%  
Depreciation Rs m1621,777 9.1%   
Interest Rs m38240 15.9%   
Profit before tax Rs m6,2152,905 213.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,203511 431.0%   
Profit after tax Rs m4,0122,394 167.6%  
Gross profit margin %15.913.7 115.9%  
Effective tax rate %35.417.6 201.5%   
Net profit margin %12.27.3 166.8%  
BALANCE SHEET DATA
Current assets Rs m22,65519,455 116.4%   
Current liabilities Rs m6,68110,076 66.3%   
Net working cap to sales %48.428.6 169.5%  
Current ratio x3.41.9 175.6%  
Inventory Days Days6598 66.2%  
Debtors Days Days2967 43.5%  
Net fixed assets Rs m83520,260 4.1%   
Share capital Rs m213252 84.2%   
"Free" reserves Rs m16,71526,633 62.8%   
Net worth Rs m16,92826,886 63.0%   
Long term debt Rs m02,340 0.0%   
Total assets Rs m24,16241,173 58.7%  
Interest coverage x163.713.1 1,250.0%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.40.8 171.2%   
Return on assets %16.86.4 262.0%  
Return on equity %23.78.9 266.2%  
Return on capital %36.910.8 343.2%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m36915,642 2.4%   
Fx outflow Rs m3,8074,884 77.9%   
Net fx Rs m-3,43810,759 -32.0%   
CASH FLOW
From Operations Rs m1,5273,411 44.8%  
From Investments Rs m-2,148-1,354 158.7%  
From Financial Activity Rs m-1,024-1,304 78.5%  
Net Cashflow Rs m-1,646753 -218.5%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 11.4 69.3%  
FIIs % 0.1 25.3 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 17.4 98.3%  
Shareholders   18,270 36,892 49.5%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   CADILA HEALTHCARE  SANOFI INDIA  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Oct 18, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS